Diatherix Revenue and Competitors
Estimated Revenue & Valuation
- Diatherix's estimated annual revenue is currently $26M per year.
- Diatherix's estimated revenue per employee is $155,000
Employee Data
- Diatherix has 168 Employees.
- Diatherix grew their employee count by -13% last year.
Diatherix Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $11.2M | 72 | 9% | N/A | N/A |
#2 | $0.9M | 6 | 200% | N/A | N/A |
#3 | $3.7M | 24 | 14% | N/A | N/A |
#4 | $2.3M | 15 | -25% | N/A | N/A |
#5 | $18M | 116 | -1% | N/A | N/A |
#6 | $0.9M | 6 | -33% | N/A | N/A |
#7 | $3.4M | 22 | 0% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $26M | 168 | -13% | N/A | N/A |
What Is Diatherix?
A unique laboratory providing accurate and actionable results in one day for infectious diseases and antibiotic resistance genes utilizing innovative molecular technologies, including proprietary TEM-PCRᅢᄁ¬ダᅡᄁ. Diatherix Eurofins distinctions: - Delivers one-day results - Identifies bacteria regardless of recent antibiotic use - Offers simplicity of single-sample collection - Identifies difficult-to-culture pathogens - Yields a high level of sensitivity and specificity
keywords:N/AN/A
Total Funding
168
Number of Employees
$26M
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Diatherix News
Diatherix Laboratories, Gen-Probe, Qiagen, F. Hoffmann-La Roche, Cepheid, Life Technologies Corporation, Meridian Biosciences,...
... F.Hoffmann-La Roche, Hain Lifescience, Biomerieux, 3M, Bio-Rad Laboratories, Abacus Diagnostica, Abbott, Puritan Medical, Diatherix.
Previously he served as the Chief Scientific Officer and Clinical Laboratory Director for Diatherix-Eurofins, in Huntsville, Alabama.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $56.9M | 168 | 1% | N/A |
#2 | $56.9M | 168 | 14% | N/A |
#3 | $61M | 168 | 8% | N/A |
#4 | $56.9M | 168 | -6% | N/A |
#5 | $46.1M | 171 | 9% | N/A |